Scienion company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired



About Scienion

Scienion offers complete solutions for parallel bioanalytics and high throughput production/screening of microarrays in genomics and proteomics. The company specializes in ultra low volume liquid handling, particularly for precious and sensitive compounds of biological or chemical origin.On August 20th, 2020, Scienion was acquired by Cellink at a valuation of $94.83M.

Scienion Headquarter Location

Volmerstrasse 7b

Berlin, D-12489,


+49 (0) 30 6392 17 00

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Scienion

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Scienion is included in 1 Expert Collection, including Omics.



1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Scienion Patents

Scienion has filed 8 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Cell biology
  • Colloidal chemistry
patents chart

Application Date

Grant Date


Related Topics




Cell biology, Quantum mechanics, Fluid dynamics, Colloidal chemistry, Biotechnology


Application Date


Grant Date



Related Topics

Cell biology, Quantum mechanics, Fluid dynamics, Colloidal chemistry, Biotechnology



Latest Scienion News

BICO Announces Million-Dollar Contract for 3D Printed Joint Implants

Dec 14, 2021

BICO Announces Million-Dollar Contract for 3D Printed Joint Implants December 13, 2021 Danish AM Hub is a national 3D printing group that organizes a large meet-up with the goal of educating and aiding its members in all things 3D printing. Several places... December 6, 2021 Senior vice president of Strategic Growth at Stratasys, Pat Carey talks to us about the company’s new product portfolio. What does it mean for partners and customers that the company... November 29, 2021 Having previously worked for Bond3D and Admatec, Michiel de Bruijcker is now doing something very new and exciting in 3D printing. With Poly Products, he’s printing large-scale structures and parts. Using... Objectify 3DPOD Episode 86: Pat Carey, Stratasys SVP of Strategic Growth 3DPOD Episode 85: Large Format 3D Printing with Poly Products’ Michiel de Bruijcker Search Contact us below to learn more Share this Article For five years, Nanochon has been developing a 3D-printed implantable device and novel nanomaterial to treat cartilage loss and damage in joints as an alternative to knee replacements. Now, BICO ( formerly Cellink ) and the Washinton D.C.-based MedTech startup are teaming up to develop 3D printed regenerative joint implants that could start clinical trials as soon as 2023. As part of the deal, Nanochon will purchase $1.5 million worth of products and services from BICO’s bio automation services subsidiary Scienion to create the joint implants, which promise faster and more successful recoveries for patients while reducing costs to health providers, payers, and patients. At the same time, BICO will invest $400,000 in Nanochon’s Seed funding round to help advance its regenerative medicine technology, scale its manufacturing processes, and accelerate clinical trials. The deal aligns with a crucial part of BICO’s Next Generation Core Industrial Ecosystems that enable tissue engineering , diagnostics, multi-omics , and cell line development. Nanochon has developed highly-engineered implants for clinical trials. Image courtesy of Nanochon. “Nanochon’s approach to regenerative joint replacement has the potential to improve the lives of tens of millions of people each year,” explained Erik Gatenholm, CEO and co-founder of BICO. “We’re thrilled to leverage BICO’s bio automation manufacturing and technology expertise to help bring this product to millions of patients around the world.” The agreement will provide BICO’s company Scienion, the opportunity to become Nanochon’s contract manufacturer for cartilage resurfacing implants. The process will leverage several key technologies from the BICO portfolio to enable what is described as a “first of its kind solution” and will also make Scienion a key manufacturing partner for Nanochon over the coming decade. Founded in 2016 by mechanical engineer and life science entrepreneur Ben Holmes and tissue engineer Nathan Castro, Nanochon targets 3D printed products for soft tissue repair in orthopedics. Their first proprietary product, Chondrograft, is a 3D printed polymer implant awaiting FDA approval that fills and regenerates damaged areas of the cartilage surface in joints, typically associated with sports injuries and osteoarthritis. If left untreated, these injuries can cause the patient pain, lead to advanced joint disease, and the need for knee replacement surgery. So Nanochon’s ultimate goal is to commercialize a treatment with much better outcomes and be widely accessible to patients and surgeons. Built upon research for scaling up existing experimental materials to meet clinical needs, Holmes and Castro saw potential in a composite material called nanostructured polyurethane (nPU) as a cartilage replacement due to its unique chemical and physical properties, which allow it to support rapid stem cell growth and tissue formation. Holmes was exploring strategies for scaling up existing experimental materials to meet clinical needs and discovered that 3D printed nPU has mechanical properties similar to cartilage and can support vascularized bone growth, which is essential for integrating any joint implant and its clinical success. Nanochon has developed highly-engineered implants for clinical trials. Image courtesy of Nanochon. The duo developed the new proprietary material for a new type of cartilage implant that can replace lost cartilage on a short-term basis and can fuse with the body in the longer term. The implant is targeted at knee injury patients who are younger and more active, typically under 55 years old. The startup detected that most of these patients want to return to more strenuous activities. Current treatment options (like metallic joint replacements) are not good enough, mainly due to invasiveness, complications, or general lack of effectiveness. Almost one million hip and knee replacement surgeries are performed in the United States every year alone, projected to grow 673% to 3.5 million procedures per year. In fact, the U.S. Centers for Medicare & Medicaid Services estimates that aging Americans will drive annual healthcare spending to $6 trillion by 2027, with much of that coming from aging-related disorders like osteoporosis. Worldwide, estimated orthopedic joint replacement surgeries are roughly 7.7 million, according to GlobalSurg , with a market size of $20 billion in 2019. How the Nanochon medical device is used in joints. Image courtesy of Nanochon. Hip and knee replacements are the most commonly performed joint replacements today. Still, they are expected to fail after 15-20 years due to a lack of organic cartilage growth and the highly disruptive nature of the surgery. Instead, Nanochon’s novel regenerative method would ideally solve this by replacing a highly invasive replacement surgery with a minimally invasive procedure, where 3D printed structures made of a novel polymer nanomaterial are implanted into damaged cartilage to promote healthy cartilage growth. Working towards that goal, Nanochon has worked with clinical and research partners to conduct several validating and de-risking studies, including a small animal study with Matthew Oetgen, the Chief of Orthopedic Surgery and Sports Medicine at Children’s National Medical Center, and an extensive animal proof of concept trial with Colorado clinical trial management service company CARE Research . Additionally, in 2017 Nanochon received a Phase I SBIR from the National Science Foundation to develop a production-ready 3D printed medical device for cartilage repair in the knee made from new tissue growth materials and designs compatible with selective laser sintering. The team also executed a manufacturing feasibility study with Belgian 3D printing company Materialise , a leader in 3D printed implants. However, through this new sales deal, Nanochon could become a springboard for future implant designs and cartilage restoration initiatives. Likewise, BICO will continue leveraging 3D printing for healthcare solutions, incorporating even more companies into its customer portfolio.

  • When was Scienion founded?

    Scienion was founded in 2001.

  • Where is Scienion's headquarters?

    Scienion's headquarters is located at Volmerstrasse 7b, Berlin.

  • What is Scienion's latest funding round?

    Scienion's latest funding round is Acquired.

  • Who are the investors of Scienion?

    Investors of Scienion include BICO, 3i Group, Peppermint VenturePartners, S-Venture Capital Dortmund, IBB Beteiligungsgesellschaft and 6 more.

  • Who are Scienion's competitors?

    Competitors of Scienion include HTG Molecular Diagnostics, WaferGen Bio-systems, Expression Analysis, BioSystem Development, TwoF and 13 more.

You May Also Like


Pepscan provides peptide-based products & services offering knowledge of peptides for drug discovery collaborations. At its end-to-end facility in Lelystad, the Netherlands, Pepscan offers a range of patented technologies, phage display capabilities, a lead-optimization array platform, and production facilities for R&D- to GMP-grade peptides, including libraries and neoantigen vaccines. Among its patents is the CLIPS technology, which locks peptides into active conformations. With its epitope mapping service platform, Pepscan also supports biotech companies in developing their antibody pipelines. The underlying protein mimicry platform delivers binding insights, even in cases where other technologies, such as linear, fall short.

Neuromedical Systems

Neuromedical Systems, Inc. a development stage company develops, manufactures and markets systems for computer assisted screening of pap smears and other cytological specimans. The company's product papnet testing system is used in laboratories in detection of abnormal cells on pap smears. Papnet is also used in detection of bladder and lung cancer. During the year, the company acquired New System International, Ltd. The company has international operations in Europe, Israel, Asia and Australia.

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.


Employing recent advances in sequencing, ASPE bead array, microarray technology, Q'Array is poised to provide a range of DNA testing, including genetic, chromosomal, biochemical, pharmacogenomics, paternity, and forensic identity testing.


Chalex Corporation's precision-made chambered McMaster counting slides are used by researchers, laboratories, nematologists and veterinary practitioners throughout the world. Made of clear durable acrylic for long-lasting use, the company's slides also feature exact volumes thanks to injection-molded accuracy which yield consistent test results compared to other slides with handmade chamber spacers. The quality of these slides make them the standard the world over.

CAPE Technologies

CAPE Technologies, of South Portland created a practical immunoassay-based test kits for dioxin and dioxin-like PCBs. The kits provide near real time analysis in a simple field lab, at lower cost, with less equipment, and with fewer people, than conventional methods. CAPE's dioxin kit is the only rapid dioxin screening method accepted by the U.S. Environmental Protection Agency (EPA) for solid waste analysis. A third kit is also available for rapid field analysis of total PCBs. CAPE's kits are marketed by distributors in Australia, Japan, Italy, Taiwan, China, and Finland, and directly through its web site to the rest of the world. CAPE Technologies maintains local ties with the University of New England, the University of Southern Maine, and the University of Maine at Orono. Dr. Robert Harrison of Cape Elizabeth is co-founder and president.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.